USANA Health Sciences (USNA) and Nutra Pharma (NPHC) Financial Comparison

USANA Health Sciences (NYSE:USNA) and Nutra Pharma (OTCMKTS:NPHC) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, risk and profitability.

Risk & Volatility

USANA Health Sciences has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Nutra Pharma has a beta of 6.24, meaning that its stock price is 524% more volatile than the S&P 500.

Valuation & Earnings

This table compares USANA Health Sciences and Nutra Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
USANA Health Sciences $1.05 billion 2.75 $62.53 million $4.06 29.58
Nutra Pharma $120,000.00 6.67 -$4.02 million N/A N/A

USANA Health Sciences has higher revenue and earnings than Nutra Pharma.

Analyst Ratings

This is a summary of current ratings and price targets for USANA Health Sciences and Nutra Pharma, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
USANA Health Sciences 0 0 2 0 3.00
Nutra Pharma 0 0 0 0 N/A

USANA Health Sciences currently has a consensus target price of $135.00, suggesting a potential upside of 12.42%. Given USANA Health Sciences’ higher probable upside, analysts clearly believe USANA Health Sciences is more favorable than Nutra Pharma.

Institutional and Insider Ownership

54.5% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 0.0% of Nutra Pharma shares are owned by institutional investors. 53.2% of USANA Health Sciences shares are owned by insiders. Comparatively, 20.9% of Nutra Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares USANA Health Sciences and Nutra Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
USANA Health Sciences 7.57% 29.67% 21.58%
Nutra Pharma -4,741.67% N/A -1,740.23%

Summary

USANA Health Sciences beats Nutra Pharma on 9 of the 11 factors compared between the two stocks.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition. It also provides Sensé—beautiful science products, such as personal care products that support healthy skin and hair through topical nourishment, moisturization, and protection; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.

Nutra Pharma Company Profile

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating back pain, neck pain, headaches, joint pain, migraines, and neuralgia, as well as a topical gel for treating joint pain, neck pain, arthritis pain, and pain associated with repetitive stress; Pet Pain-Away, an over-the-counter pain reliever to treat pain in cats and dogs; Luxury Feet, an over-the-counter pain reliever to treat foot pain from high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Nyloxin, a topical therapy for chronic pain in horses. It is also developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases, including human immunodeficiency virus/AIDS and herpes; RPI-78 for pain and arthritis; and RPI-70 for pain. The company has a collaboration agreement with the International Security Group to develop nerve agent counter measures. Nutra Pharma Corp. was founded in 2000 and is based in Coral Springs, Florida.

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply